Medical management of non-obstructive azoospermia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/53180 |
Resumo: | Non-obstructive azoospermia is diagnosed in approximately 10% of infertile men. It represents a failure of spermatogenesis within the testis and, from a management standpoint, is due to either a lack of appropriate stimulation by gonadotropins or an intrinsic testicular impairment. The former category of patients has hypogonadotropic hypogonadism and benefits from specific hormonal therapy. These men show a remarkable recovery of spermatogenic function with exogenously administered gonadotropins or gonadotropin-releasing hormone. This category of patients also includes some individuals whose spermatogenic potential has been suppressed by excess androgens or steroids, and they also benefit from medical management. The other, larger category of non-obstructive azoospermia consists of men with an intrinsic testicular impairment where empirical medical therapy yields little benefit. The primary role of medical management in these men is to improve the quantity and quality of sperm retrieved from their testis for in vitro fertilization. Gonadotropins and aromatase inhibitors show promise in achieving this end point. |
id |
USP-19_6447e06ae0ada9f70f21027cf12a9e34 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/53180 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Medical management of non-obstructive azoospermia InfertilityDrug TherapyGonadotropinsHypogonadismAromatase Inhibitors Non-obstructive azoospermia is diagnosed in approximately 10% of infertile men. It represents a failure of spermatogenesis within the testis and, from a management standpoint, is due to either a lack of appropriate stimulation by gonadotropins or an intrinsic testicular impairment. The former category of patients has hypogonadotropic hypogonadism and benefits from specific hormonal therapy. These men show a remarkable recovery of spermatogenic function with exogenously administered gonadotropins or gonadotropin-releasing hormone. This category of patients also includes some individuals whose spermatogenic potential has been suppressed by excess androgens or steroids, and they also benefit from medical management. The other, larger category of non-obstructive azoospermia consists of men with an intrinsic testicular impairment where empirical medical therapy yields little benefit. The primary role of medical management in these men is to improve the quantity and quality of sperm retrieved from their testis for in vitro fertilization. Gonadotropins and aromatase inhibitors show promise in achieving this end point. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2013-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/5318010.6061/clinics/2013(Sup01)08Clinics; Vol. 68 No. spe (2013); 75-79Clinics; v. 68 n. spe (2013); 75-79Clinics; Vol. 68 Núm. spe (2013); 75-791980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/53180/57241Kumar, Rajeevinfo:eu-repo/semantics/openAccess2013-04-08T20:47:20Zoai:revistas.usp.br:article/53180Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2013-04-08T20:47:20Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Medical management of non-obstructive azoospermia |
title |
Medical management of non-obstructive azoospermia |
spellingShingle |
Medical management of non-obstructive azoospermia Kumar, Rajeev Infertility Drug Therapy Gonadotropins Hypogonadism Aromatase Inhibitors |
title_short |
Medical management of non-obstructive azoospermia |
title_full |
Medical management of non-obstructive azoospermia |
title_fullStr |
Medical management of non-obstructive azoospermia |
title_full_unstemmed |
Medical management of non-obstructive azoospermia |
title_sort |
Medical management of non-obstructive azoospermia |
author |
Kumar, Rajeev |
author_facet |
Kumar, Rajeev |
author_role |
author |
dc.contributor.author.fl_str_mv |
Kumar, Rajeev |
dc.subject.por.fl_str_mv |
Infertility Drug Therapy Gonadotropins Hypogonadism Aromatase Inhibitors |
topic |
Infertility Drug Therapy Gonadotropins Hypogonadism Aromatase Inhibitors |
description |
Non-obstructive azoospermia is diagnosed in approximately 10% of infertile men. It represents a failure of spermatogenesis within the testis and, from a management standpoint, is due to either a lack of appropriate stimulation by gonadotropins or an intrinsic testicular impairment. The former category of patients has hypogonadotropic hypogonadism and benefits from specific hormonal therapy. These men show a remarkable recovery of spermatogenic function with exogenously administered gonadotropins or gonadotropin-releasing hormone. This category of patients also includes some individuals whose spermatogenic potential has been suppressed by excess androgens or steroids, and they also benefit from medical management. The other, larger category of non-obstructive azoospermia consists of men with an intrinsic testicular impairment where empirical medical therapy yields little benefit. The primary role of medical management in these men is to improve the quantity and quality of sperm retrieved from their testis for in vitro fertilization. Gonadotropins and aromatase inhibitors show promise in achieving this end point. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/53180 10.6061/clinics/2013(Sup01)08 |
url |
https://www.revistas.usp.br/clinics/article/view/53180 |
identifier_str_mv |
10.6061/clinics/2013(Sup01)08 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/53180/57241 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; Vol. 68 No. spe (2013); 75-79 Clinics; v. 68 n. spe (2013); 75-79 Clinics; Vol. 68 Núm. spe (2013); 75-79 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1800222759762001920 |